On behalf of a major European venture capital investor, Alacrita reviewed the business plan and competitive positioning of a novel point-of-care diagnostics company. The company was developing a fully integrated point of care diagnostic instrument platform to enable sensitive and fast tests in the ICU/ER/OR.
The technology was at an early stage, with the company looking to establish the platform’s USPs and then freeze the design of its cartridge and analyzer. To supplement its internal capability, the investor wanted to reinforce its due diligence of the company by calling on external expertise.
The project was lead by Alacrita’s lead diagnostics consultant who has over 20 years’ commercial experience in the diagnostics industry. Our analysis demonstrated that although the novel platform had superior economics relative to key competitors, its potential lead could be easily eroded by the time needed to broaden the test menu.Back